GB201812992D0 - Liposomes - Google Patents

Liposomes

Info

Publication number
GB201812992D0
GB201812992D0 GBGB1812992.4A GB201812992A GB201812992D0 GB 201812992 D0 GB201812992 D0 GB 201812992D0 GB 201812992 A GB201812992 A GB 201812992A GB 201812992 D0 GB201812992 D0 GB 201812992D0
Authority
GB
United Kingdom
Prior art keywords
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1812992.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Greenwich
Original Assignee
University of Greenwich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Greenwich filed Critical University of Greenwich
Priority to GBGB1812992.4A priority Critical patent/GB201812992D0/en
Publication of GB201812992D0 publication Critical patent/GB201812992D0/en
Priority to CA3108864A priority patent/CA3108864A1/en
Priority to PCT/GB2019/052239 priority patent/WO2020030923A1/en
Priority to JP2021531197A priority patent/JP7687683B2/ja
Priority to US17/266,904 priority patent/US12233162B2/en
Priority to AU2019317788A priority patent/AU2019317788B2/en
Priority to EP19755418.1A priority patent/EP3833330A1/en
Priority to CN201980063528.4A priority patent/CN113286578A/zh
Priority to IL280703A priority patent/IL280703A/en
Priority to US19/021,759 priority patent/US20250152513A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24083—Anthrax lethal factor endopeptidase (3.4.24.83)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1812992.4A 2018-08-09 2018-08-09 Liposomes Ceased GB201812992D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1812992.4A GB201812992D0 (en) 2018-08-09 2018-08-09 Liposomes
CN201980063528.4A CN113286578A (zh) 2018-08-09 2019-08-09 制备脂质体的方法
US17/266,904 US12233162B2 (en) 2018-08-09 2019-08-09 Method for preparing liposomes
PCT/GB2019/052239 WO2020030923A1 (en) 2018-08-09 2019-08-09 Method for preparing liposomes
JP2021531197A JP7687683B2 (ja) 2018-08-09 2019-08-09 リポソームの調製方法
CA3108864A CA3108864A1 (en) 2018-08-09 2019-08-09 Method for preparing liposomes
AU2019317788A AU2019317788B2 (en) 2018-08-09 2019-08-09 Method for preparing liposomes
EP19755418.1A EP3833330A1 (en) 2018-08-09 2019-08-09 Method for preparing liposomes
IL280703A IL280703A (en) 2018-08-09 2021-02-07 Method for preparing liposomes
US19/021,759 US20250152513A1 (en) 2018-08-09 2025-01-15 Method for preparing liposomes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1812992.4A GB201812992D0 (en) 2018-08-09 2018-08-09 Liposomes

Publications (1)

Publication Number Publication Date
GB201812992D0 true GB201812992D0 (en) 2018-09-26

Family

ID=63667012

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1812992.4A Ceased GB201812992D0 (en) 2018-08-09 2018-08-09 Liposomes

Country Status (9)

Country Link
US (2) US12233162B2 (enExample)
EP (1) EP3833330A1 (enExample)
JP (1) JP7687683B2 (enExample)
CN (1) CN113286578A (enExample)
AU (1) AU2019317788B2 (enExample)
CA (1) CA3108864A1 (enExample)
GB (1) GB201812992D0 (enExample)
IL (1) IL280703A (enExample)
WO (1) WO2020030923A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11931458B2 (en) 2021-01-11 2024-03-19 Babak Ghalili Exosome systems, products and methods
CN114259573B (zh) * 2022-01-06 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种含有胆碱酯酶重活化剂的脑靶向脂质体及其制备方法和用途
WO2023195976A1 (en) * 2022-04-05 2023-10-12 Babak Ghalili Exosome systems, products and methods
CN115990270B (zh) * 2022-07-14 2023-08-11 郑州大学 一种抑制肿瘤干性的纳米载体及其制备方法和应用
CN118806683B (zh) * 2023-09-26 2024-11-22 天津医科大学眼科医院 一种成体干细胞源的细胞内纳米囊泡在抗衰老和毛囊再生中的应用
CN118272405B (zh) * 2024-02-28 2025-01-07 浙江大学杭州国际科创中心 一种高效分泌纳米抗体药物的基因工程菌及其应用
WO2025259543A1 (en) * 2024-06-09 2025-12-18 Mercury Bio, Inc. Targeted delivery of cas13d and associated guide shrna to silence targeted rnas via yeast extracellular vesicles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096926A2 (en) * 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
US20150079631A1 (en) 2012-03-16 2015-03-19 The General Hospital Corporation Microvesicle-mediated delivery of therapeutic molecules
GB201311057D0 (en) * 2013-06-21 2013-08-07 Univ Greenwich Antisense oligonucleotide compositions
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US20150275229A1 (en) 2014-03-25 2015-10-01 William Douglas Meadow, JR. Self-iterating exosomal vector for effective biomolecular transfers
WO2016187717A1 (en) 2015-05-26 2016-12-01 Exerkine Corporation Exosomes useful for genome editing
GB2552473A (en) 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Also Published As

Publication number Publication date
IL280703A (en) 2021-03-25
AU2019317788A1 (en) 2021-03-04
CA3108864A1 (en) 2020-02-13
US20250152513A1 (en) 2025-05-15
EP3833330A1 (en) 2021-06-16
US12233162B2 (en) 2025-02-25
JP2021533825A (ja) 2021-12-09
US20210338584A1 (en) 2021-11-04
AU2019317788B2 (en) 2024-08-15
CN113286578A (zh) 2021-08-20
WO2020030923A1 (en) 2020-02-13
JP7687683B2 (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
GB201917181D0 (en) No details
GB201917180D0 (en) No details
GB201917178D0 (en) No details
DK3793565T3 (en) Mcl-1-inhibitorer
GB201910775D0 (en) No Details
DK3759096T3 (en) Cd73-inhibitorer
GB202017924D0 (en) No details
CA185384S (en) Casque
GB201912486D0 (en) No details
DK3773537T3 (en) Stat3-hæmmere
GB201918422D0 (en) No details
CA184994S (en) Uroflowmeter
CA184991S (en) Uroflowmeter
GB201908106D0 (en) No details
GB202004524D0 (en) No details
DK3801538T3 (en) Tlr7-agonister
GB202007832D0 (en) No details
GB201918330D0 (en) No details
GB201913500D0 (en) No details
GB201908250D0 (en) No details
GB201806174D0 (en) Improved downlighter
GB201905867D0 (en) No details
GB201805799D0 (en) b
DK3829449T3 (en) Biopsistanse
GB201802830D0 (en) Smartvalve

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)